Large-cap Health Care company Pfizer has moved 1.4% so far today on a volume of 2,861,231, compared to its average of 24,143,255. In contrast, the S&P 500 index moved 1.0%.
Pfizer trades -18.63% away from its average analyst target price of $44.09 per share. The 23 analysts following the stock have set target prices ranging from $32.0 to $75.0, and on average have given Pfizer a rating of buy.
Anyone interested in buying PFE should be aware of the facts below:
-
Pfizer's current price is -20.9% below its Graham number of $45.38, which implies the stock has a margin of safety
-
Pfizer has moved -20.0% over the last year, and the S&P 500 logged a change of 17.0%
-
Based on its trailing earnings per share of 3.76, Pfizer has a trailing 12 month Price to Earnings (P/E) ratio of 9.5 while the S&P 500 average is 15.97
-
PFE has a forward P/E ratio of 10.9 based on its forward 12 month price to earnings (EPS) of $3.3 per share
-
The company has a price to earnings growth (PEG) ratio of -0.67 — a number near or below 1 signifying that Pfizer is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 2.05 compared to its sector average of 4.16
-
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
-
Based in New York, the company has 83,000 full time employees and a market cap of $202.55 Billion. Pfizer currently returns an annual dividend yield of 4.6%.